113 related articles for article (PubMed ID: 25160651)
1. Discovery of a small-molecule inhibitor of STAT3 by ligand-based pharmacophore screening.
Leung KH; Liu LJ; Lin S; Lu L; Zhong HJ; Susanti D; Rao W; Wang M; Che WI; Chan DS; Leung CH; Chan PW; Ma DL
Methods; 2015 Jan; 71():38-43. PubMed ID: 25160651
[TBL] [Abstract][Full Text] [Related]
2. Identification of a natural product-like STAT3 dimerization inhibitor by structure-based virtual screening.
Liu LJ; Leung KH; Chan DS; Wang YT; Ma DL; Leung CH
Cell Death Dis; 2014 Jun; 5(6):e1293. PubMed ID: 24922077
[TBL] [Abstract][Full Text] [Related]
3. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity.
Siddiquee K; Zhang S; Guida WC; Blaskovich MA; Greedy B; Lawrence HR; Yip ML; Jove R; McLaughlin MM; Lawrence NJ; Sebti SM; Turkson J
Proc Natl Acad Sci U S A; 2007 May; 104(18):7391-6. PubMed ID: 17463090
[TBL] [Abstract][Full Text] [Related]
4. Chemical probes that competitively and selectively inhibit Stat3 activation.
Xu X; Kasembeli MM; Jiang X; Tweardy BJ; Tweardy DJ
PLoS One; 2009; 4(3):e4783. PubMed ID: 19274102
[TBL] [Abstract][Full Text] [Related]
5. Pharmacophore modeling for the identification of small-molecule inhibitors of TACE.
Liu LJ; Leung KH; Lin S; Chan DS; Susanti D; Rao W; Chan PW; Ma DL; Leung CH
Methods; 2015 Jan; 71():92-7. PubMed ID: 25260600
[TBL] [Abstract][Full Text] [Related]
6. Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening.
Hao W; Hu Y; Niu C; Huang X; Chang CP; Gibbons J; Xu J
Bioorg Med Chem Lett; 2008 Sep; 18(18):4988-92. PubMed ID: 18768317
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening.
Zhang M; Zhu W; Li Y
Eur J Med Chem; 2013 Apr; 62():301-10. PubMed ID: 23376248
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design.
Yu W; Xiao H; Lin J; Li C
J Med Chem; 2013 Jun; 56(11):4402-12. PubMed ID: 23651330
[TBL] [Abstract][Full Text] [Related]
9. Identification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validation.
Szelag M; Czerwoniec A; Wesoly J; Bluyssen HA
PLoS One; 2015; 10(2):e0116688. PubMed ID: 25710482
[TBL] [Abstract][Full Text] [Related]
10. Novel STAT3 small-molecule inhibitors identified by structure-based virtual ligand screening incorporating SH2 domain flexibility.
Kong R; Bharadwaj U; Eckols TK; Kolosov M; Wu H; Cruz-Pavlovich FJS; Shaw A; Ifelayo OI; Zhao H; Kasembeli MM; Wong STC; Tweardy DJ
Pharmacol Res; 2021 Jul; 169():105637. PubMed ID: 33932608
[TBL] [Abstract][Full Text] [Related]
11. Electrochemical detection of the Fc-STAT3 phosphorylation and STAT3-Fc-STAT3 dimerization and inhibition.
Martic S; Rains MK; Haftchenary S; Shahani VM; Kraskouskaya D; Ball DP; Gunning PT; Kraatz HB
Mol Biosyst; 2014 Mar; 10(3):576-80. PubMed ID: 24402062
[TBL] [Abstract][Full Text] [Related]
12. Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation.
Park IH; Li C
J Mol Recognit; 2011; 24(2):254-65. PubMed ID: 21360612
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors.
Furtek SL; Matheson CJ; Backos DS; Reigan P
Oncotarget; 2016 Nov; 7(47):77998-78008. PubMed ID: 27793003
[TBL] [Abstract][Full Text] [Related]
14. Strategies and Approaches of Targeting STAT3 for Cancer Treatment.
Furtek SL; Backos DS; Matheson CJ; Reigan P
ACS Chem Biol; 2016 Feb; 11(2):308-18. PubMed ID: 26730496
[TBL] [Abstract][Full Text] [Related]
15. Alpha-Based Multiplexed Assay for Identifying SH2 Domain Antagonists.
Asai A; Takakuma K
Methods Mol Biol; 2017; 1555():351-356. PubMed ID: 28092042
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor.
Coleman DR; Ren Z; Mandal PK; Cameron AG; Dyer GA; Muranjan S; Campbell M; Chen X; McMurray JS
J Med Chem; 2005 Oct; 48(21):6661-70. PubMed ID: 16220982
[TBL] [Abstract][Full Text] [Related]
17. Methods for generating and applying pharmacophore models as virtual screening filters and for bioactivity profiling.
Vuorinen A; Schuster D
Methods; 2015 Jan; 71():113-34. PubMed ID: 25461773
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potential inhibitors for stat3: ligand based 3D pharmacophore, virtual screening, molecular docking, dynamic studies and
Lakshmanan K; T K P; K Pai SR; Rajagopal K; Byran G
J Biomol Struct Dyn; 2022; 40(21):11320-11338. PubMed ID: 34463213
[TBL] [Abstract][Full Text] [Related]
19. Novel high-throughput screening system for identifying STAT3-SH2 antagonists.
Uehara Y; Mochizuki M; Matsuno K; Haino T; Asai A
Biochem Biophys Res Commun; 2009 Mar; 380(3):627-31. PubMed ID: 19285012
[TBL] [Abstract][Full Text] [Related]
20. A novel non-phosphorylated potential antitumoral peptide inhibits STAT3 biological activity.
Dourlat J; Liu WQ; Sancier F; Edmonds T; Pamonsinlapatham P; Cruzalegui F; Garbay C
Biochimie; 2009 Aug; 91(8):996-1002. PubMed ID: 19470402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
